01:23 AM EDT, 08/13/2026 (MT Newswires) -- Kuros Biosciences (KURN.SW) said Thursday it swung to a net profit in the first half, while revenue rose year over year. Net profit for the six months ended June 30 was $4.4 million, compared with a loss of $2 million a year earlier. EPS was $0.11, compared with a loss per share of $0.05. The biopharmaceutical company's revenue from product sales was $92.4 million, compared with $63.5 million a year ago. Looking ahead, the company confirmed its sales growth outlook of at least 35% in 2026, and affirmed its expectation for 2028 sales of between $300 million and $330 million.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.